Laboratory Features of Cutaneous Lupus Erythematosus

  • Shuntaro Shinada
  • Daniel J. Wallace


Systemic Lupus Erythematosus Aplastic Anemia Anticardiolipin Antibody Complete Blood Cell Count Cutaneous Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM (1998) Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129:716–718PubMedGoogle Scholar
  2. Blum C, Zillikens D, Tony HP, Hartmann AA, Burg A (1993) Soluble interleukin-2 receptor as activity parameter in serum of systemic and discoid lupus erythematosus. Hautarzt 44:290–295PubMedGoogle Scholar
  3. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE (1993) Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119:1198–1208PubMedGoogle Scholar
  4. Callen JP (1982) Chronic cutaneous lupus erythematosus: clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 118:412–416CrossRefPubMedGoogle Scholar
  5. Callen JP, Klein J (1988) Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in 72 patients. Arthritis Rheum 31:1007–1013PubMedGoogle Scholar
  6. Callen JP, Fowler JF, Kulick KB (1985) Serologic and clinical features of patients with discoid lupus erythematosus: relationship of antibodies to single-stranded deoxyribonucleic acid and of other antinuclear antibody subsets to clinical manifestations. J Am Acad Dermatol 13:748–755PubMedGoogle Scholar
  7. Callen JP, Kulick KB, Stelzer G, Fowler JF (1986) Subacute cutaneous lupus erythematosus. Clinical, serologic, and immunogenetic studies of 49 patients seen in a non-referral setting. J Am Acad Dermatol 15:1227–1237PubMedGoogle Scholar
  8. Chelbus E, Wolska H, Blaszyk M, Jablonska S (1998) Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications. J Am Acad Dermatol 38:405–412PubMedGoogle Scholar
  9. Choudhry V, Madan N, Sood SK, Ghai OP (1978) Chloroquine-induced haemolysis and acute renal failure in subjects with G-6-PD deficiency. Trop Geogr Med 30:331–335PubMedGoogle Scholar
  10. Cohen MR, Crosby D (1994) Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol 21:1665–1669PubMedGoogle Scholar
  11. Committee on Safety of Medicines/Medicines Control Agency (1997) Blood dyscrasias and other ADRs with low-dose methotrexate. Current Problems 23:12–18Google Scholar
  12. Custer RP (1946) Aplastic anemia in soldiers treated with Atabrine (quinacrine). Am J Med Sci 212:211–224Google Scholar
  13. Dahl MGC (1984) Folate depletion in psoriatics on methotrexate. Br J Dermatol 111(Suppl 26):18PubMedGoogle Scholar
  14. Dodd HJ, Kirby JD, Munro DD (1985) Megaloblastic anaemia in psoriatic patients treated with methotrexate. Br J Dermatol 112:630–631PubMedGoogle Scholar
  15. Ettinger WH, Hazzard WR (1988) Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism 37:1055–1058CrossRefPubMedGoogle Scholar
  16. Fonseca E, Alvarez R, Gonzalez MR, Pascual D (1992) Prevalence of anticardiolipin antibodies in subacute cutaneous lupus erythematosus. Lupus 1:265–268PubMedGoogle Scholar
  17. Franceschini F, Calzavara-Pinton P, Quinzanini M, Cavazzana I, Bettoni L, Zane C, Facchetti F, Airo P, McCauliffe DP, Cattaneo R (1998) Chilbains lupus erythematosus is associated with antibodies to SSA/Ro. Lupus 8:215–219CrossRefGoogle Scholar
  18. Gaffney K, Scott DG (1998) Azathioprine and cyclophasphamide in the treatment of rheumatoid arthritis. Br J Rheum 37:824–836CrossRefGoogle Scholar
  19. Johansson-Stephansson E, Koskimes S, Partanen J, Kariniemi AL (1989) Subacute cutaneous lupus erythematosus: genetic markers and clinical and immunological findings in patients. Arch Dermatol 125:791–796CrossRefPubMedGoogle Scholar
  20. Kersley GD, Palin AG (1959) Amodiaquine and hydroxychloroquine in rheumatoid arthritis. Lancet ii:886–888CrossRefGoogle Scholar
  21. Konstadoulakis MM, Kroubouzos G, Tosca A, Piperingos G, Marafelia P, Konstadoulakis M, Varelzidis A, Koutras DA (1993) Thyroid autoantibodies in the subsets of lupus erythematosus: correlation with other autoantibodies and thyroid function. Thyroidol Clin Exp 5:1–7PubMedGoogle Scholar
  22. Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME (1994) Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 37:1829–1830PubMedGoogle Scholar
  23. Landewe RB, Vergouwen MS, Goeei The SG, Van Rijthoven AW, Breedveld FC, Dijkmans BA (1995) Antimalarial drug induced decrease in creatinine clearance. J Rheumatol 22:34–37PubMedGoogle Scholar
  24. Lee LA, Roberts CM, Frank MB, McCubbin VR, Reichlin M (1994) The autoantibody response to Ro/SSA in cutaneous lupus erythematosus. Arch Dermatol 130:1262–1268CrossRefPubMedGoogle Scholar
  25. Ludolph A, Matz DR (1982) Electrophysiologic changes in thalidomide neuropathy under treatment for discoid LE. EEG EMG 13:167–170PubMedGoogle Scholar
  26. Mayou SC, Wojnorowska F, Lovell CR, Asherson RA, Leigh IM (1988) Anticardiolipin and antinuclear antibodies in discoid lupus erythematosus — their clinical significance. Clin Exp Dermatol 13:389–392PubMedGoogle Scholar
  27. Meyerson MA, Cohen PR (1994) Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus. Mayo Clin Proc 69:1159–1162PubMedGoogle Scholar
  28. Millard LG, Rowell NR (1979) Abnormal laboratory test results and their relationship to prognosis in discoid lupus erythematosus. A long-term follow-up study of 92 patients. Arch Dermatol 115:1055–1058CrossRefPubMedGoogle Scholar
  29. Mok CC, Lau CS, Woon Sing Wong R (1998) Toxicities of dapsone in the treatment of cutaneous manifestations of rheumatic diseases. J Rheumatol 25:1246–1247PubMedGoogle Scholar
  30. Musabayane CT, Ndhlovu CE, Balment RJ (1994) The effects of oral chloroquine administration on kidney function. Renal Fail 16:221–228Google Scholar
  31. Neuberger J (1995) Methotrexate and liver disorders. Prescribers’ J 35:158–63Google Scholar
  32. O’Loughlin S, Schroeter AL, Jordan RE (1978) A study of lupus erythematosus with particular reference to generalized discoid lupus. Br J Dermatol 99:1–11PubMedGoogle Scholar
  33. Orth DN, Kovacs WJ (1998) The adrenal cortex. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR (eds) Williams textbook of endocrinology, 9th ed. WB Saunders, Philadelphia, pp 517–664Google Scholar
  34. Petri M, Lakatta C, Magder L, Goldman D (1994) Effects of prednisone and hydroxychloroquine on coronary artery disease rise factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 96:254–259CrossRefPubMedGoogle Scholar
  35. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR (1991) Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21:55–64CrossRefPubMedGoogle Scholar
  36. Polano MK, Cats A, van Olden GAJ (1965) Agranulocytosis following treatment with hydroxychloroqine sulfate. Lancet 1:1275CrossRefGoogle Scholar
  37. Provost TT, Ratrie H (1990) Autoantibodies and autoantigens in lupus erythematosus and Sjogren’s syndrome. Curr Probl Dermatol 2:150–208Google Scholar
  38. Prystowsky SD, Kerndon JH, Gilliam JN (1975) Chronic cutaneous lupus erythematosus (DLE): a clinical and laboratory investigation of 80 patients. Medicine 55:183–191Google Scholar
  39. Rowell NR (1984) The natural history of lupus erythematosus. Clin Exp Dermatol 9:217–231PubMedGoogle Scholar
  40. Sanchez NP, Peters MS, Winkelmann RK (1981) The histopathology of lupus erythematosus panniculitis. J Am Acad Dermatol 5:673–680PubMedGoogle Scholar
  41. Schimmer BP, Parker KL (1996) Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JE, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds) The pharmacological basis of therapeutics, 9th ed. McGraw-Hill, New York, pp 1459–1485Google Scholar
  42. Shi SY, Feng SF, Liao KH, Fang L, Kang KF (1987) Clinical study of 30 cases of subacute cutaneous lupus erythematosus. Chin Med J 100:45–48PubMedGoogle Scholar
  43. Sontheimer RD (1989) Subacute cutaneous lupus erythematosus: a decade’s perspective. Med Clin North Am 73:1073–1090PubMedGoogle Scholar
  44. Sontheimer RD, Provost TT (1997) Cutaneous manifestations of lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 5th ed. Williams & Wilkins, Philadelphia, pp 569–623Google Scholar
  45. Sontheimer RD, Maddison PJ, Richlin M, Jordon RE, Stasny P, Gilliam JN (1982) Serologic and HLA associations in subacute cutaneous lupus erythematosus: a clinical subset of lupus erythematosus. Ann Intern Med 97:664–671PubMedGoogle Scholar
  46. Sturdevant RA, Singleton JW, Derern JL, Law DH, McCleery JL (1979) Azathioprine-related pancreatitis in patients with Crohn’s disease. Gastroenterology 77:883–886PubMedGoogle Scholar
  47. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) Special article: the 1982 revised criteria for the classification of systemic lupus erythmatosus. Arthritis Rheum 25:1271–1277PubMedGoogle Scholar
  48. Tebbe B, Mansmann U, Wollina U, Auer-Grumbach P, Licht-Mbalyohere A, Arensmeier M, Orfanos CE (1997) Markers in cutaneous lupus erythematosus indicating systemic involvement — a multicenter study on 296 patients. Acta Derm Venereol 77:305–308PubMedGoogle Scholar
  49. Wallace DJ (1989) The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 18:282–296CrossRefPubMedGoogle Scholar
  50. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA (1990) Cholesterol-lowering effects of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89:322–326CrossRefPubMedGoogle Scholar
  51. Wallace DJ, Pistiner M, Nessim S, Metzger AL, Klinenberg JR (1992) Cutaneous lupus erythematosus without systemic lupus erythematosus: clinical and laboratory features. Semin Arthritis Rheum 21:221–226CrossRefPubMedGoogle Scholar
  52. Winkelmann RK, Peters MS (1982) Lupus panniculitis. Dermatol Update 135Google Scholar
  53. Wysenbeek AJ, Guedj D, Amit M, Weinberger A (1992) Rash in systemic lupus erythematosus: prevalence and relation to cutaneous and non-cutaneous disease manifestations. Ann Rheum Dis 51:717–719PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 2005

Authors and Affiliations

  • Shuntaro Shinada
  • Daniel J. Wallace

There are no affiliations available

Personalised recommendations